- ECONOMIC IMPACT -

Latest update: 22 July 

The global economy is forecasted to return to pre-crisis levels by the end of 2021 or early 2022. 

According to the Australian Bureau of Statistics, the country added 30,000 jobs in June 2021.

7.4%

The Congressional Budget Office of the US has forecast US real GDP growth at 7.4% in 2021 and at 3.1% in 2022.

4%

The World Bank has downgraded the economic growth forecast for East Asia and the Pacific, excluding China, to 4% in 2021.

Impact of Covid-19 on equity indices

- SECTOR IMPACT: PHARMA -

Latest update: 04 August

industry development

3.75%

Clinical trials using virtual components have increased even more rapidly in 2020 and 2021 with 3.75% of clinical trials using decentalised clinical trial components recorded in Q2 2021.

>200

The number of jobs related to virtual trials has increased over the past year. Data shows an increase from 30 posted jobs in Q3 2019 to 160 in Q3 2020, with further increases to over 200 in Q1 and Q2 2021.

Vaccination developments

With multiple vaccines having shown impressive efficacy, notably for reductions in the need for hospitalisation and mortality, the window for utility for Covid-19 therapies may be rapidly contracting.


However, this may be offset increased illness caused by the rise of vaccine-resistant variants and shortages of vaccines in certain countries, such as India.


Low vaccination rates in localised areas could lead to ‘hyperlocal outbreaks’ where communities surrounded by high vaccination areas could experience outbreaks in localised clusters. 

Key pharma market developments

Share this article

Go to article: Home | Once more unto the (data) breachGo to article: In this issueGo to article: ContentsGo to article: SHL MedicalGo to article: SHL Medical Company Insight Go to article: Datwyler Company InsightGo to article: DatwylerGo to article: LabcorpGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: BaxterGo to article: Sukano Company InsightGo to article: SukanoGo to article: CommentGo to article: Use of off-label therapies increases the need for reliable clinical trial dataGo to article: Unmet needs remain in the neuroendocrine tumour treatment paradigmGo to article: Drinking alcohol raises risk of oesophageal and other cancersGo to article: Verder Company InsightGo to article: VerderGo to article: RegPakGo to article: Avery DennisonGo to article: In DepthGo to article: Pharma cybersecurity breaches to know and learn fromGo to article: The drugs treating alcoholism Go to article: In with the old: how an established vaccine is fuelling Covid-19 treatmentGo to article: How are hospitals tackling pharmaceutical pollution?Go to article: After Covid-19, mRNA technology aims to revolutionise the flu shotGo to article: Pushing for a UK genomics revolutionGo to article: MicronovaGo to article: Pfeiffer VacuumGo to article: HOF SonderanlagenbauGo to article: In DataGo to article: Data: pharma subsidiaries Go to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue